Viatris to acquire Pacira Biosciences in $1.65 billion deal
VTRS•Viatris said it has agreed to acquire Pacira Biosciences for $1.65 billion, adding the pain therapy maker’s products to its portfolio as it seeks to expand its innovative medicines business.
1. Acquisition agreement
Viatris said it has agreed to acquire Pacira Biosciences for $1.65 billion. The deal would add Pacira’s pain therapy products to Viatris’ portfolio as the company seeks to expand its innovative medicines business.
